Challenges and considerations for antifungal prophylaxis in children with acute myeloid leukemia
Details
Publication Year 2024-08-12,Volume 17,Issue #10,Page 679-686
Journal Title
Expert Review of Hematology
Publication Type
Review
Abstract
INTRODUCTION: Children receiving treatment for acute myeloid leukemia (AML) are at high risk of invasive fungal disease (IFD). Evidence from pediatric studies support the efficacy of antifungal prophylaxis in reducing the burden of IFD in children receiving therapy for AML, yet existing antifungal agents have specific limitations and comparative data to inform the optimal prophylactic approach are lacking. AREAS COVERED: This review summarizes the epidemiology of invasive fungal disease (IFD) and current antifungal prophylaxis recommendations for children with acute myeloid leukemia (AML). Challenges with currently available antifungal agents and considerations related to the changing landscape of AML therapy are reviewed. A keyword search was conducted to identify pediatric studies regarding IFD and antifungal prophylaxis in children with AML up to December 2023. EXPERT OPINION: Children undergoing treatment for AML are recommended to receive antifungal prophylaxis to reduce risk of IFD, with tolerability, pharmacokinetics, feasibility of administration, and drug interactions all factors that require consideration in this context. With increased use of novel targeted agents for AML therapy, together with the development of new antifungal agents, data from well-designed clinical studies to optimize prophylactic approaches will be essential to limit the burden of IFD in this vulnerable cohort.
Publisher
Taylor & Francis
Keywords
Acute myeloid leukemia; FLT3 inhibitors; antifungal prophylaxis; hypomethylating agents; invasive fungal disease; menin inhibitors; venetoclax
Department(s)
Infectious Diseases
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-09-24 02:20:20
Last Modified: 2024-09-24 02:22:35

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙